Data Under Review
Some valuation figures for this stock are being recalibrated. Hidden fields will return after data review.
Reported as ticker: VIVIMEDLAB· We're continuously improving data quality. Contact support if this persists.
VIVIMED LABS LIMITED
VIVIMEDLAB · General/Diversified · NSE
₹6
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for VIVIMEDLAB yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
3/9
Economic Moat
None
Confidence
18%
ROE
90.9%
Debt/Equity
9.67
WACC
11.1%
Market Cap
₹53.31 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-2.9%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
-17.3×
EBIT covers interest
Current Ratio
0.80×
Short-term liquidity
Asset Turnover
0.09×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-21.1%
3-year revenue growth
Revenue CAGR (5Y)
-35.7%
5-year revenue growth
Ratio Trends
VIVIMEDLAB · last 4 annual periods
ROE
90.9%
ROCE
-2.9%
Operating Margin
—
Debt / Equity
9.67×
PE
—
EV / EBITDA
—
Historical Financials
VIVIMEDLAB · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹861 Cr | ₹237 Cr | — | ₹149 Cr | ₹116 Cr | -39.4% |
| EBITDA | — | ₹-8.0 Cr | ₹-187 Cr | ₹-24.7 Cr | ₹-9.9 Cr | — |
| EBIT | ₹-21.9 Cr | ₹-25.1 Cr | ₹-295 Cr | ₹-43.4 Cr | — | — |
| PAT | ₹-77.8 Cr | ₹-67.7 Cr | ₹-329 Cr | ₹-45.4 Cr | ₹-32.0 Cr | — |
| EPS (diluted) | ₹-9.11 | ₹-7.92 | ₹-38.46 | ₹-5.32 | — | — |
| CFO | ₹567 Cr | ₹27.5 Cr | ₹35.3 Cr | ₹-24.0 Cr | ₹-1.8 Cr | — |
| CapEx | — | ₹-16.4 Cr | ₹-5.0 Cr | ₹-2.0 Cr | ₹-4.5 Cr | — |
| FCF | — | ₹11.1 Cr | ₹30.4 Cr | ₹-26.0 Cr | ₹-6.3 Cr | — |
| Total Assets | — | ₹1266 Cr | ₹995 Cr | ₹951 Cr | ₹921 Cr | -7.7% |
| Total Debt | — | ₹359 Cr | ₹381 Cr | ₹379 Cr | ₹376 Cr | +1.2% |
| Shareholders' Equity | — | ₹364 Cr | ₹39.4 Cr | ₹-5.5 Cr | ₹-35.2 Cr | — |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
VIVIMEDLAB vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
BIOFILCHEM BIOFILCHEM | — | — | Pending | 12.9% | — |
MANGALAM MANGALAM | — | — | Pending | -43.1% | — |
LASA LASA | — | — | Pending | -17.6% | — |
VAISHALI VAISHALI | — | — | Pending | 1.3% | — |
PAR PAR | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
2 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
—
Last payout
2018-09-19
₹0.40
Peak payout
₹0.40
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of VIVIMEDLAB →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for VIVIMEDLAB →
Compare
Head-to-head with peers
Compare VIVIMEDLAB side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse VIVIMEDLABNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.